For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Research and development, net | 899 | 1,120 | ||
| General and administrative | 1,148 | 1,453 | ||
| Operating loss | -2,047 | -2,573 | ||
| Financial income (expense), net | -59 | -330 | ||
| Net loss | -2,106 | -2,903 | ||
| Earnings per share, basic | -0.19 | -0.34 | ||
| Earnings per share, diluted | -0.19 | -0.34 | ||
| Weighted average number of shares outstanding, basic | 11,008,047 | 8,620,400 | ||
| Weighted average number of shares outstanding, diluted | 11,008,047 | 8,620,400 | ||
BRAINSTORM CELL THERAPEUTICS INC. (BCLI)
BRAINSTORM CELL THERAPEUTICS INC. (BCLI)